Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cell and Islet Co-transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pancreatitis patients who undergo TP-IAT.~* \>18 years of age.~* Patients with BMI from 18.5 to 30.~* Renal function: \>90mls/min/1.73m squared~* Normal INR/PT/PTT values for MUSC clinical laboratory standards~* Diabetes free before surgery (fasting blood glucose\<125mg/dl).~* No prior pancreatic surgery with the exception of transduodenal sphincteroplasty or Whipple/Beger procedure.~* Patients with normal liver function as measured by serum levels of aminotransferase including alanine aminotransferase (ALT), and aspartate aminotransferase (AST), and total bilirubin levels.~Exclusion Criteria:~* Patients whose Hemoglobin, Hematocrit, and Platelet count are above or below normal values for MUSC clinical laboratory standards.~* Patients who has hematological malignancy.~* Patients who are under immunosuppression.~* Patients with marked calcification disease on CT scan.~* Patients with severe fibrosis and atrophy on pancreas MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients will receive standard islet transplantation.
- autologous mesenchymal stromal cell (Type: EXPERIMENTAL): Patients will receive MSCs together with standard islet transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).